 |
4 Diseases |  |
49 Trials |
|
49 Trials |  |
1092 News |  |
| «12...45678910111213141516 |
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
New P1 trial: Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Nov 17, 2016
P1, N=27, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||||| New P2 trial: FRACTION-GC: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (clinicaltrials.gov) - Oct 16, 2016
P2, N=910, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||| Opdivo (nivolumab) / BMS
Enrollment change, Monotherapy: CheckMate 358: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (clinicaltrials.gov) - Sep 26, 2016
P1/2, N=500, Recruiting, Sponsor: Bristol-Myers Squibb
N=199 --> 500
- || Opdivo (nivolumab) / BMS
Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Sep 8, 2016
P1/2, N=240, Recruiting, Sponsor: Bristol-Myers Squibb
N=199 --> 500 Trial primary completion date: Aug 2016 --> Mar 2017
- ||| Opdivo (nivolumab) / BMS
Enrollment open, Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker: Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) (clinicaltrials.gov) - Aug 30, 2016
P1, N=68, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Aug 2016 --> Mar 2017 Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Aug 2016 | Trial primary completion date: Mar 2018 --> Aug 2018
- ||| Opdivo (nivolumab) / BMS
Enrollment change, MSi-H Biomarker, PD(L)-1 Biomarker: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Aug 9, 2016
P1/2, N=240, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Aug 2016 | Trial primary completion date: Mar 2018 --> Aug 2018 N=96 --> 240
- || Trial primary completion date: FRACTION-Lung: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 9, 2016
P2, N=504, Recruiting, Sponsor: Bristol-Myers Squibb
N=96 --> 240 Trial primary completion date: Apr 2020 --> Apr 2021
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=132, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Apr 2020 --> Apr 2021 Trial primary completion date: Jun 2018 --> Feb 2018
- ||| Enrollment change: FRACTION-Lung: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 13, 2016
P2, N=504, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2018 --> Feb 2018 N=685 --> 504
- | Biomarker, Enrollment open, BRCA Biomarker, PD(L)-1 Biomarker: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Jun 9, 2016
P2, N=3000, Recruiting, Sponsor: National Cancer Institute (NCI)
N=685 --> 504 Suspended --> Recruiting
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - May 27, 2016
P1/2, N=132, Recruiting, Sponsor: Bristol-Myers Squibb
Suspended --> Recruiting Trial primary completion date: Nov 2019 --> Jun 2018
- |||| Enrollment open: FRACTION-Lung: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 22, 2016
P2, N=685, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Nov 2019 --> Jun 2018 Not yet recruiting --> Recruiting
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Phase classification, Enrollment change, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - May 19, 2016
P1/2, N=132, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Phase classification: P1 --> P1/2 | N=108 --> 132 | Trial primary completion date: Jun 2018 --> Nov 2019
- ||||| New P2 trial: FRACTION-Lung: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 25, 2016
P2, N=685, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- || Opdivo (nivolumab) / BMS
Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Apr 13, 2016
P1/2, N=96, Recruiting, Sponsor: Bristol-Myers Squibb
Phase classification: P1 --> P1/2 | N=108 --> 132 | Trial primary completion date: Jun 2018 --> Nov 2019 Trial primary completion date: Dec 2016 --> Sep 2016
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment change, Trial primary completion date: RELATIVITY-020: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors (clinicaltrials.gov) - Apr 13, 2016
P1, N=360, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2016 --> Sep 2016 N=540 --> 360 | Trial primary completion date: Sep 2016 --> May 2018
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Checkpoint inhibition: Neoadjuvant and Adjuvant Checkpoint Blockade (clinicaltrials.gov) - Feb 4, 2016
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=540 --> 360 | Trial primary completion date: Sep 2016 --> May 2018 Not yet recruiting --> Recruiting
- ||| Opdivo (nivolumab) / BMS
New P1 trial, PD(L)-1 Biomarker: Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) (clinicaltrials.gov) - Jan 20, 2016
P1, N=68, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- Biomarker, BRCA Biomarker, PD(L)-1 Biomarker: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Dec 24, 2015
P2, N=3000, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2021 --> Jun 2022
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date, Trial primary completion date, Checkpoint inhibition: Neoadjuvant and Adjuvant Checkpoint Blockade (clinicaltrials.gov) - Dec 17, 2015
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Aug 2021 --> Jun 2022 Initiation date: Nov 2015 --> Feb 2016 | Trial primary completion date: Nov 2018 --> Feb 2019
- Biomarker, BRCA Biomarker, PD(L)-1 Biomarker: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Nov 24, 2015
P2, N=3000, Suspended, Sponsor: National Cancer Institute (NCI)
Initiation date: Nov 2015 --> Feb 2016 | Trial primary completion date: Nov 2018 --> Feb 2019 Trial primary completion date: Jun 2022 --> Aug 2021
- Biomarker, BRCA Biomarker, PD(L)-1 Biomarker: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Nov 6, 2015
P2, N=3000, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2022 --> Aug 2021 Recruiting --> Suspended
- |||| Opdivo (nivolumab) / BMS
Enrollment open, Monotherapy: CheckMate 358: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=199, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Suspended Not yet recruiting --> Recruiting
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment change: RELATIVITY-020: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors (clinicaltrials.gov) - Sep 4, 2015
P1, N=540, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting N=198 --> 540
- Biomarker, BRCA Biomarker, PD(L)-1 Biomarker: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Aug 17, 2015
P2, N=3000, Recruiting, Sponsor: National Cancer Institute (NCI)
N=198 --> 540 Not yet recruiting --> Recruiting
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, Checkpoint inhibition: Neoadjuvant and Adjuvant Checkpoint Blockade (clinicaltrials.gov) - Aug 10, 2015
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Biomarker, BRCA Biomarker, PD(L)-1 Biomarker: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Jul 6, 2015
P2, N=3000, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Oct 2015 --> Jul 2015
- ||||| Opdivo (nivolumab) / BMS
New P1/2 trial, Monotherapy: CheckMate 358: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (clinicaltrials.gov) - Jul 2, 2015
P1/2, N=200, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment change: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - Jun 15, 2015
P1, N=108, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Oct 2015 --> Jul 2015 N=88 --> 108
- | Biomarker, BRCA Biomarker, PD(L)-1 Biomarker: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Jun 6, 2015
P2, N=3000, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial initiation date: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - May 6, 2014
P1, N=88, Recruiting, Sponsor: Bristol-Myers Squibb
N=88 --> 108 Initiation date: Mar 2014 --> Feb 2014
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial initiation date: RELATIVITY-020: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors (clinicaltrials.gov) - May 6, 2014
P1, N=168, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Mar 2014 --> Feb 2014 Initiation date: Nov 2013 --> Oct 2013
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - May 6, 2014
P1, N=88, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Nov 2013 --> Oct 2013 Trial primary completion date: Feb 2016 --> Jun 2018
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial completion date: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - May 6, 2014
P1, N=88, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Feb 2016 --> Jun 2018 Trial completion date: Feb 2017 --> Jun 2018
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment open: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - Mar 26, 2014
P1, N=84, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Feb 2017 --> Jun 2018 Not yet recruiting --> Recruiting
- |||| Opdivo (nivolumab) / BMS
Enrollment open, MSi-H Biomarker, PD(L)-1 Biomarker: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Mar 24, 2014
P1/2, N=96, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
New P1 trial: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - Feb 11, 2014
P1, N=84, Recruiting, Sponsor: Bristol-Myers Squibb
- ||||| Opdivo (nivolumab) / BMS
New P1/2 trial, MSi-H Biomarker, PD(L)-1 Biomarker: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Feb 9, 2014
P1/2, N=96, Recruiting, Sponsor: Bristol-Myers Squibb
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment open: RELATIVITY-020: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors (clinicaltrials.gov) - Oct 30, 2013
P1, N=168, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
New P1 trial: RELATIVITY-020: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors (clinicaltrials.gov) - Oct 21, 2013
P1, N=168, Recruiting, Sponsor: Bristol-Myers Squibb